SELLAS Life Sciences Group, Inc. Operating Expenses
SELLAS Life Sciences Group, Inc. (SLS) reported Operating Expenses of $31.87 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2017-03-15
- SELLAS Life Sciences Group, Inc. operating expenses for the quarter ending 2013-12-31 was $6.13M, a 9.90% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating expenses for the quarter ending 2013-09-30 was $7.76M, a 40.41% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating expenses for the quarter ending 2013-06-30 was $7.99M, a 40.52% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating expenses for the quarter ending 2013-03-31 was $6.61M, a 49.91% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating expenses for fiscal 2016 was $31.87M, a 6.88% decline from fiscal 2015.
- SELLAS Life Sciences Group, Inc. operating expenses for fiscal 2015 was $34.22M, a 22.05% decline from fiscal 2014.
- SELLAS Life Sciences Group, Inc. operating expenses for fiscal 2014 was $43.90M, a 54.09% increase from fiscal 2013.
- SELLAS Life Sciences Group, Inc. operating expenses for fiscal 2013 was $28.49M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed | Operating Expenses 102 month | Operating Expenses 105 month | Operating Expenses 108 month | Operating Expenses 111 month | Operating Expenses 114 month | Operating Expenses 120 month | Operating Expenses 123 month | Operating Expenses 126 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $31.87M 10-K · filed 2017-03-15 | |||||||||||||||
| 2015-12-31 | $34.22M 10-K · filed 2017-03-15 | |||||||||||||||
| 2014-12-31 | $43.90M 10-K · filed 2017-03-15 | $61.54M 10-K · filed 2015-03-05 | ||||||||||||||
| 2013-12-31 | $6.13M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2016-04-15 | $13.89M derived: sum of 2 quarters · filed 2016-04-15 | $21.88M derived: sum of 3 quarters · filed 2016-04-15 | $28.49M 10-K/A · filed 2016-04-15 | $36.33M 10-K · filed 2014-03-17 | |||||||||||
| 2013-09-30 | $7.76M 10-Q/A · filed 2013-11-07 | $15.75M derived: sum of 2 quarters · filed 2013-11-07 | $22.36M 10-Q/A · filed 2013-11-07 | $27.94M derived: sum of 4 quarters · filed 2015-12-04 | ||||||||||||
| 2013-06-30 | $7.99M 10-Q · filed 2013-08-09 | $14.60M 10-Q · filed 2013-08-09 | $20.18M derived: sum of 3 quarters · filed 2015-12-04 | $25.70M derived: sum of 4 quarters · filed 2015-12-04 | $86.68M 10-Q · filed 2013-08-09 | |||||||||||
| 2013-03-31 | $6.61M 10-Q · filed 2013-05-09 | $12.19M derived: sum of 2 quarters · filed 2015-12-04 | $17.72M derived: sum of 3 quarters · filed 2015-12-04 | $23.40M derived: sum of 4 quarters · filed 2015-12-04 | $78.69M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $5.58M derived: 8-K 12 month − 10-Q/A 9 month · filed 2015-12-04 | $11.11M derived: sum of 2 quarters · filed 2015-12-04 | $16.79M derived: sum of 3 quarters · filed 2015-12-04 | $21.20M 8-K · filed 2015-12-04 | $72.08M 10-K · filed 2013-03-12 | |||||||||||
| 2012-09-30 | $5.53M 10-Q/A · filed 2013-11-07 | $11.21M derived: sum of 2 quarters · filed 2013-11-07 | $15.62M 10-Q/A · filed 2013-11-07 | $19.21M derived: sum of 4 quarters · filed 2014-03-17 | $66.50M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | $5.68M 10-Q · filed 2013-08-09 | $10.09M 10-Q · filed 2013-08-09 | $13.69M derived: sum of 3 quarters · filed 2014-03-17 | $17.12M derived: sum of 4 quarters · filed 2014-03-17 | $60.98M 10-Q · filed 2012-08-14 | |||||||||||
| 2012-03-31 | $4.41M 10-Q · filed 2013-05-09 | $5.61M 10-Q · filed 2012-05-14 | $8.00M derived: sum of 2 quarters · filed 2014-03-17 | $11.44M derived: sum of 3 quarters · filed 2014-03-17 | $13.72M derived: sum of 4 quarters · filed 2014-03-17 | $96.57M 10-Q · filed 2012-05-14 | ||||||||||
| 2011-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $7.03M derived: sum of 2 quarters · filed 2014-03-17 | $9.31M derived: sum of 3 quarters · filed 2014-03-17 | $12.49M 10-K · filed 2014-03-17 | $20.79M 10-K · filed 2012-03-28 | $90.96M 10-K · filed 2012-03-28 | ||||||||||
| 2011-09-30 | $3.44M 10-Q · filed 2012-11-13 | $5.08M 10-Q · filed 2011-11-14 | $5.71M derived: sum of 2 quarters · filed 2012-11-13 | $8.89M 10-Q · filed 2012-11-13 | $14.98M 10-Q · filed 2011-11-14 | $14.68M derived: sum of 4 quarters · filed 2012-11-13 | $85.15M 10-Q · filed 2011-11-14 | |||||||||
| 2011-06-30 | $2.28M 10-Q · filed 2012-08-14 | $4.62M 10-Q/A · filed 2011-10-28 | $5.46M 10-Q · filed 2012-08-14 | $9.90M 10-Q/A · filed 2011-10-28 | $11.25M derived: sum of 3 quarters · filed 2012-08-14 | $14.97M derived: sum of 4 quarters · filed 2012-08-14 | $80.07M 10-Q/A · filed 2011-10-28 | |||||||||
| 2011-03-31 | $5.28M 10-Q · filed 2012-05-14 | $8.97M derived: sum of 2 quarters · filed 2012-05-14 | $12.69M derived: sum of 3 quarters · filed 2012-05-14 | $17.44M derived: sum of 4 quarters · filed 2012-05-14 | ||||||||||||
| 2010-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-28 | $7.42M derived: sum of 2 quarters · filed 2012-03-28 | $12.17M derived: sum of 3 quarters · filed 2012-03-28 | $16.63M 10-K · filed 2012-03-28 | ||||||||||||
| 2010-09-30 | $3.72M 10-Q · filed 2011-11-14 | $8.47M derived: sum of 2 quarters · filed 2011-11-14 | $12.93M 10-Q · filed 2011-11-14 | |||||||||||||
| 2010-06-30 | $4.75M 10-Q/A · filed 2011-10-28 | $9.21M 10-Q/A · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |